These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22545088)

  • 1. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state.
    Patkar A; Gilmer W; Pae CU; Vöhringer PA; Ziffra M; Pirok E; Mulligan M; Filkowski MM; Whitham EA; Holtzman NS; Thommi SB; Logvinenko T; Loebel A; Masand P; Ghaemi SN
    PLoS One; 2012; 7(4):e34757. PubMed ID: 22545088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial.
    Potkin SG; Keck PE; Segal S; Ice K; English P
    J Clin Psychopharmacol; 2005 Aug; 25(4):301-10. PubMed ID: 16012271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
    Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
    J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.
    Keck PE; Versiani M; Potkin S; West SA; Giller E; Ice K;
    Am J Psychiatry; 2003 Apr; 160(4):741-8. PubMed ID: 12668364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder.
    Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
    J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):545-57. PubMed ID: 24111980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
    J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder.
    Papakostas GI; Vitolo OV; Ishak WW; Rapaport MH; Zajecka JM; Kinrys G; Mischoulon D; Lipkin SH; Hails KA; Abrams J; Ward SG; Meisner A; Schoenfeld DA; Shelton RC; Winokur A; Okasha MS; Bari MA; Fava M
    J Clin Psychiatry; 2012 Dec; 73(12):1541-7. PubMed ID: 23290327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
    Keck PE; Reeves KR; Harrigan EP;
    J Clin Psychopharmacol; 2001 Feb; 21(1):27-35. PubMed ID: 11199944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 13-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder.
    Patkar AA; Pae CU; Vöhringer PA; Mauer S; Narasimhan M; Dalley S; Loebel A; Masand PS; Ghaemi SN
    J Clin Psychopharmacol; 2015 Jun; 35(3):319-23. PubMed ID: 25882763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone monotherapy in bipolar II depression: an open trial.
    Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
    J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.
    Mischoulon D; Shelton RC; Baer L; Bobo WV; Curren L; Fava M; Papakostas GI
    J Clin Psychiatry; 2017 Apr; 78(4):449-455. PubMed ID: 27835715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial.
    Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; DiPierro M; Cardoos A; Papakostas GI
    Int Clin Psychopharmacol; 2014 Nov; 29(6):332-8. PubMed ID: 24815673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
    Keck PE; Calabrese JR; McQuade RD; Carson WH; Carlson BX; Rollin LM; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2006 Apr; 67(4):626-37. PubMed ID: 16669728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
    Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
    J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.
    Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
    J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):531-44. PubMed ID: 24111983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
    Keck PE; Calabrese JR; McIntyre RS; McQuade RD; Carson WH; Eudicone JM; Carlson BX; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2007 Oct; 68(10):1480-91. PubMed ID: 17960961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
    Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
    J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.